维克萨斯综合征和阿尔茨海默病 - - 有没有联系?
Aleksandra Sowa1, Marta Malicka1, Magdalena Biernacka1
1Department of Psychiatry, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Brain sciences
|June 26, 2025
概括
维克萨斯综合征和阿尔茨海默氏症有着共同的炎症和血管问题. 了解这些联系可能会为这两种复杂的疾病揭示新的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 维克萨斯综合征是一种罕见的自身炎症性疾病,具有UBA1突变,全身炎症和血液学问题.
- 阿尔茨海默病 (AD) 是一种进展性痴呆症,其特征是神经退行,粉样质斑块,团和神经炎症.
- 这两种情况都涉及系统性炎症,蛋白质错折和血管功能障碍,这表明潜在的共享途径.
研究的目的:
- 探索VEXAS综合征和阿尔茨海默病之间的潜在病理生理联系.
- 研究系统性炎症,神经炎症和血管功能障碍在这两种疾病中的作用.
- 突出显示在VEXAS综合征中泛素-蛋白酶体系统,特别是UBA1突变的意义及其对AD的潜在相关性.
主要方法:
- 文献综述和对VEXAS综合征和阿尔茨海默病现有研究的综合.
- 对重叠机制的比较分析,如炎症,蛋白质错折和血管变化.
- 在这两种情况中检查了泛素-蛋白酶体系统的作用.
主要成果:
- 维克萨斯综合征中的系统性炎症可能会通过增加细胞因子通过血脑屏障而加剧AD中的神经炎症.
- 共同的血管功能障碍可以协同加速两个条件的个体的认知衰退.
- 无素-蛋白酶体系统的破坏,包括VEXAS中的UBA1突变,会影响与神经退行相关的细胞平衡.
结论:
- 维克萨斯综合征和AD共享关键的病理生理路径,特别是炎症和血管功能障碍.
- 对这些重叠机制的进一步研究对于开发新型治疗策略至关重要.
- 研究不同的和共享的分子基础可以提供对这两种疾病的更深入的见解,有助于治疗并发症病例.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在UBA1中,UBA1是UBA1的.这就是VEXAS.认知能力下降 认知能力下降痴呆症 痴呆症是一种痴呆症.这是一种炎症炎症炎症炎症.神经退行症的神经退行症更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
8.0K
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
40.4K
相关概念视频
01:26Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
01:30Dementia
182
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
182
01:29Biological Causes of Schizophrenia
156
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
156
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
461
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
461
01:30Atherosclerosis I: Introduction
93
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
93